BBS-Bioactive Bone Substitutes Oyj
BBS-Bioactive Bone Substitutes Oyj, a biomedical technology company, develops, manufactures, and commercializes bioactive medical devices and implants for orthopedic surgery in Finland. It offers ARTEBONE, an orthobiological product based on tricalcium phosphate and natural spectrum of bone proteins used primarily for the treatment of bone defects and healing problems in extremities, such as foot… Read more
BBS-Bioactive Bone Substitutes Oyj (BONEH) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of June 2024: -0.416x
Based on the latest financial reports, BBS-Bioactive Bone Substitutes Oyj (BONEH) has a cash flow conversion efficiency ratio of -0.416x as of June 2024.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-1.58 Million) by net assets (€3.79 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
BBS-Bioactive Bone Substitutes Oyj - Cash Flow Conversion Efficiency Trend (2015–2023)
This chart illustrates how BBS-Bioactive Bone Substitutes Oyj's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
BBS-Bioactive Bone Substitutes Oyj Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of BBS-Bioactive Bone Substitutes Oyj ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
ZWACK UNICUM
MU:ZWC1
|
0.131x |
|
HUA YIN INTL HLDGS LTD
F:CL7
|
N/A |
|
Av Gad Holdings Ltd
TA:AVGD
|
-0.357x |
|
Stayble Therapeutics AB
ST:STABL
|
-0.219x |
|
DEVRY EDUCATION GRP - Dusseldorf Stock Exchang
DU:DVY
|
0.064x |
|
Imaspro Corporation Bhd
KLSE:7222
|
0.036x |
|
Korea Petrochemical Industrial Co. Ltd.
KQ:006650
|
N/A |
|
Clean Motion AB
ST:CLEMO
|
0.012x |
Annual Cash Flow Conversion Efficiency for BBS-Bioactive Bone Substitutes Oyj (2015–2023)
The table below shows the annual cash flow conversion efficiency of BBS-Bioactive Bone Substitutes Oyj from 2015 to 2023.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2023-12-31 | €5.11 Million | €-2.92 Million | -0.572x | +13.21% |
| 2022-12-31 | €4.27 Million | €-2.82 Million | -0.659x | +4.93% |
| 2021-12-31 | €3.63 Million | €-2.52 Million | -0.693x | -74.58% |
| 2020-12-31 | €6.09 Million | €-2.42 Million | -0.397x | +15.30% |
| 2019-12-31 | €3.08 Million | €-1.44 Million | -0.469x | -21.77% |
| 2018-12-31 | €4.42 Million | €-1.70 Million | -0.385x | +61.34% |
| 2017-12-31 | €1.08 Million | €-1.08 Million | -0.996x | -738.64% |
| 2016-12-31 | €4.60 Million | €-546.00K | -0.119x | -23.33% |
| 2015-12-31 | €4.46 Million | €-430.00K | -0.096x | -- |